/Boston%20Scientific%20Corp_%20phone%20and%20website-by%20T_Schneider%20via%20Shutterstock.jpg)
With a market cap of $155.7 billion, Boston Scientific Corporation (BSX) is a global medical device company operating through three segments: Cardiovascular, Rhythm and Neuro, and MedSurg. It offers technologies such as drug-eluting stents, implantable cardiac devices, and systems for gastrointestinal, urological, and neurological treatments.
Companies valued at $10 billion or more are generally considered "large-cap" stocks, and Boston Scientific fits this criterion perfectly. Boston Scientific has pursued both organic innovation and strategic acquisitions to build a comprehensive portfolio addressing complex diseases, including coronary artery disease, chronic pain, and cancer.
However, shares of the Marlborough, Massachusetts-based company have fallen 2.8% from its 52-week high of $107.17. BSX stock has risen marginally over the past three months, slightly outperforming the broader iShares U.S. Medical Devices ETF's (IHI) 3.4% drop over the same time frame.
In the longer term, BSX stock has increased 16.6% on a YTD basis, outpacing IHI's 5.6% gain. Moreover, shares of the medical device manufacturer have soared 37.9% over the past 52 weeks, compared to IHI's 10.9% return over the same time frame.
To confirm the bullish price trend, the stock has been trading above its 50-day and 200-day moving averages since last year.
Shares of Boston Scientific rose 4.1% on Apr. 23 after a strong quarterly performance led by a 26% organic surge in cardiovascular sales to $3.1 billion, surpassing expectations. Electrophysiology sales soared 145%, while Watchman heart device sales grew 24% overall and 25% in the U.S.. Total sales rose 21% as reported to $4.7 billion and adjusted EPS jumped 34% to $0.75, beating forecasts. The company also raised its 2025 adjusted EPS guidance to $2.87 - $2.94, citing strong demand for medical devices.
In contrast, rival Abbott Laboratories (ABT) has underperformed Boston Scientific over the past 52 weeks with a 30.7% gain, but has outpaced BSX YTD with an 18.1% rise.
Due to the stock's strong price action over the past year, analysts are bullish on BSX. The stock has a consensus rating of "Strong Buy" from the 29 analysts in coverage, and the mean price target of $120.41 is a premium of 15.6% to current levels.
